Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases

Cytokine

Volumn 35, Issue 3-4, 2006, Pages 109-114

  Molnár, Ildikó ^a   Bokk, Ágota ^b  

^a Kenezy Teaching Hospital   (Hungary)

^b Ágota Bokk Genzyme   (Hungary)

Author keywords

Autoimmunity; Graves' disease; Nerve growth factor; Ophthalmopathy; Thyroid diseases

Indexed keywords

NERVE GROWTH FACTOR;

AUTOIMMUNITY; COMPARATIVE STUDY; CORRELATION ANALYSIS; ENDOCRINE OPHTHALMOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE DISEASE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; INFLAMMATION; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; THYROID DISEASE; TOXIC GOITER;

ADULT; AUTOIMMUNITY; CASE-CONTROL STUDIES; FEMALE; GOITER, NODULAR; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HASHIMOTO DISEASE; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENTS;

EID: 33751032081     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2006.08.002     Document Type: Review

References (34)

1. Mendell L.M., Albers K.M., and Davis B.M. Neurotrophins, nociceptors, and pain. Microsc Res Tech 45 (1999) 252-261
2. Moalem G., Gdalyahu A., Shani Y., Otten U., Lazarovici P., Cohen I.R., and Schwartz M. Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. J Autoimmun 15 (2000) 331-345
3. Menderes A., Yilmaz M., Vayvada H., Ozer E., and Barutcu A. Effects of nerve growth factor on the neurotization of denervated muscles. Ann Plast Surg 48 (2002) 415-422
4. Kobayashi H., Gleich G.J., Butterfield J.H., and Kita H. Human eosinophils produce neurotrophins and secrete nerve growth factor on immunologic stimuli. Blood 99 (2002) 2214-2220
5. Kyriakis J., and Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81 (2001) 807-869
6. Morgan B., Thorpe L.W., Marchetti D., and Perez-Polo J.R. Expression of nerve growth factor receptors by human peripheral blood mononuclear cells. J Neurosci Res 23 (1989) 41-45
7. Otten U., Ehrhard P., and Peck R. Nerve growth factor induces growth and differentiation of human B lymphocytes. Proc Natl Acad Sci USA 86 (1989) 10059-10063
8. Olgart C., and Frossard N. Human lung fibroblasts secrete nerve growth factor: effect of inflammatory cytokines and glucocorticoids. Eur Respir J 18 (2001) 115-121
9. Path G., Braun A., Meents N., Kerzel S., Quarcoo D., Raap U., Hoyle G.W., Nockher W.A., and Renz H. Augmentation of allergic early-phase reaction by nerve growth factor. Am J Respir Crit Care Med 166 (2002) 818-826
10. 2. Am J Physiol Endocrinol Metab 289 (2005) E62-E67
11. Nisoli E., Tonello C., Benarese M., Liberini P., and Carruba M.O. Expression of nerve growth factor in brown adipose tissue: Implications for thermogenesis and obesity. Endocrinology 137 (1996) 495-503
12. Kazim M., Goldberg R.A., and Smith T.J. Insights into the pathogenesis of thyroid-associated orbitopathy. Arch Ophthalmol 120 (2002) 380-386
13. Hiromatsu Y., Yang D., Bednarczuk T., Miyake I., Nonaka K., and Inoue Y. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 85 (2000) 1194-1199
14. Valyasevi R.W., Jyonouchi S.C., Dutton C.M., Munsakul N., and Bahn R.S. Effect of tumor necrosis factor-α, interferon-γ, and transforming growth factor-β on adipogenesis and expression of thyrotropin receptor in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab 86 (2001) 903-908
15. Kumar S., Coenen M.J., Scherer P.E., and Bahn R.S. Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 89 (2004) 930-935
16. Goodall K.L., Jackson A., Leatherbarrow B., and Whitehouse R.W. Enlargement of the tensor intermuscularis muscle in Graves' ophthalmopathy:computed tomographic and magnetic resonance imaging study. Arch Ophthalmol 113 (1995) 1286-1289
17. Fernandez M., Guiliani A., Pirondi S., D'Intino G., Giardino L., Aloe L., Levi-Montalcini R., and Calza L. Thyroid hormone administration enhances remyelination in chronic demyelinating inflammatory disease. Proc Natl Acad Sci USA 101 (2004) 16363-16368
18. Ransohoff R.M., and Trebst C. Surprising pleiotropy of nerve growth factor in the treatment of experimental autoimmune encephalomyelitis. J Exp Med 191 (2000) 1625-1629
19. Calzà L., Fernandez M., Giuliani A., Aloe L., and Giardino L. Thyroid hormone activates oligodendrocyte precursors and increases a myelin-forming protein and NGF content in the spinal cord during experimental allergic encephalomyelitis. Proc Natl Acad Sci USA 99 (2002) 3258-3263
20. Werner S.C. Modification of classification of eye changes of Graves' disease: recommendations of the Ad Hoc Committee of American Thyroid Association. J Clin Endocrinol Metab 44 (1977) 2034
21. Calzà L., Giardino L., Pozza M., Micera A., and Aloe L. Time-course changes of nerve growth factor, corticotropin-releasing hormone, and nitric oxide synthase isoforms and their possible role in the development of inflammatory response in experimental allergic encephalomyelitis. Proc Natl Acad Sci USA 94 (1997) 3368-3373
22. Baas D., Legrand C., Samarut J., and Flamant F. Persistence of oligodendrocyte precursor cells and altered myelination in optic nerve associated to retina degeneration in mice devoid of all thyroid hormone receptors. Proc Natl Acad Sci USA 99 (2002) 2907-2911
23. Ehrhard P.B., Erb P., Graumann U., Schmutz B., and Otten U. Expression of functional trk tyrosine kinase receptors after T cell activation. J Immunol 152 (1994) 2705-2709
24. Brodie C. Differential effects of Th1 and Th2 derived cytokines on NGF synthesis by mouse astrocytes. Fed Eur Biochem Societ Let 394 (1996) 117-120
25. Villislada P., Hauser S.L., Bartke I., Unger J., Heald N., Rosenberg D., Cheung S.W., Mobley W.C., Fisher S., and Genain C.P. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med 191 (2000) 1799-1806
26. Fuenzalida K.M., Aguilera M.C., Piderit D.G., Ramos P.C., Contador D., Quifiones V., Rigotti A., Bronfman F.C., and Bronfman M. Peroxisome proliferator-activated receptor gamma is a novel target of the nerve growth factor signaling pathway in PC12 cells. J Biol Chem 280 (2005) 9604-9609
27. Peeraully M.R., Jenkins J.R., and Trayhurn P. NGF gene expression and secretion in white adipose tissue: regulation in 3T3-L1 adipocytes by hormones and inflammatory cytokines. Am J Physiol Endocrinol Metab 287 (2004) E331-E339
28. Starkey K., Heufelder A., Baker G., Joba W., Evans M., Davies S., and Ludgate M. Peroxisome proliferator-activated receptor-γ in thyroid eye disease: Contraindication for thiazolidinedione use?. J Clin Endocrinol Metab 88 (2003) 55-59
29. Murphy R.A. Nerve growth factor in mouse serum and saliva: Role of the submandibular gland. Proc Natl Acad Sci USA 74 (1977) 2330-2333
30. Lambiase A., Bonini S., Manni L., Ghinelli E., Tirassa P., Rama P., and Aloe L. Intraocular production and release of nerve growth factor after iridectomy. Invest Ophthalmol Vis Sci 43 (2002) 2334-2340
31. Lambiase A., Manni L., Bonini S., Rama P., Micera A., and Aloe L. Nerve growth factor promotes corneal healing: Structural, biochemical, and molecular analyses of rat and human corneas. Invest Ophthalmol Vis Sci 41 (2000) 1063-1069
32. Kipnis J., Yoles E., Porat Z., Cohen A., Mor F., Sela M., Cohen I.R., and Schwartz M. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: Possible therapy for optic neuropathies. Proc Natl Acad Sci USA 97 (2000) 7446-7451
33. Irie Y., Mori F., Keung W.M., Mizushima Y., and Wakabayashi K. Expression of neuronal growth inhibitory factor (metallothionein-III) in the salivary gland. Physiol Res 53 (2004) 719-723
34. Tuominen I.S.J., Konttinen Y.T., Vesaluoma M.H., Moilanen J.A.O., Helintö M., and Tervo T.M.T. Corneal innervation and morphology in primary Sjögren's syndrome. Invest Ophthalmol Vis Sci 44 (2003) 2545-2549